Finance

Lists
T1EV34:BVMF
Teva Pharmaceutical Industries Bdr
98,10 R$
0,00%
(0,00) 1D
7 қаз., 13:35:03 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for T1EV34...
Mkt. cap
47,12 млрд
Avg. vol.
127,00
Volume
0,00
52-wk high
101,90 R$
52-wk low
51,60 R$
Shares outstanding
1,17 млрд
No. of employees
32 мың
Mkt. cap
47,12 млрд
Avg. vol.
127,00
Volume
0,00
52-wk high
101,90 R$
52-wk low
51,60 R$
Shares outstanding
1,17 млрд
No. of employees
32 мың
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Bdr
CEORichard Francis
Employees32 мың
Founded1944 ж. 13 ақп.
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Last report
2026 ж. 29 шіл.
Fiscal period
Q2 2026
0,02 $ / 0,11 $
-81,46%miss
Revenue / Est. (USD)
4,14 млрд / 4,03 млрд
+2,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
4,48 млрд
4,71 млрд
3,98 млрд
4,14 млрд
Cost of goods sold
2,18 млрд
2,06 млрд
2,01 млрд
1,99 млрд
Cost of revenue
2,18 млрд
2,06 млрд
2,01 млрд
1,99 млрд
Research and development expenses
256,00 млн
267,00 млн
222,00 млн
970,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973,00 млн
1,12 млрд
1,00 млрд
1,03 млрд
Operating expense
1,24 млрд
1,37 млрд
1,21 млрд
1,99 млрд
Total operating expenses
3,41 млрд
3,43 млрд
3,22 млрд
3,98 млрд
Operating income
1,07 млрд
1,28 млрд
763,00 млн
167,00 млн
Other non operating income
-27,00 млн
-
-13,00 млн
-69,00 млн
EBT including unusual items
648,00 млн
90,00 млн
436,00 млн
-455,00 млн
EBT excluding unusual items
832,00 млн
1,08 млрд
547,00 млн
-57,00 млн
Income tax expense
214,00 млн
-390,00 млн
67,00 млн
121,00 млн
Effective tax rate
33,02%
-433,33%
15,37%
-26,59%
Other operating expenses
9,00 млн
-17,00 млн
-14,00 млн
-18,00 млн
Net income
433,00 млн
480,00 млн
369,00 млн
-576,00 млн
Net profit margin
9,67%
10,19%
9,27%
-13,91%
Earnings per share
0,78
0,96
0,53
0,02
Interest and investment income
-
92,00 млн
-
-
Interest expense
-205,00 млн
-280,00 млн
-191,00 млн
-186,00 млн
Net interest expenses
-205,00 млн
-188,00 млн
-191,00 млн
-186,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,32 млрд
1,54 млрд
1,00 млрд
408,00 млн
Gain or loss from assets sale
-
-
-8,00 млн
-12,00 млн
AI content may include mistakes. Learn more
Google қолданбалары